Though still in the investigational phase, HMN-372 represents a shift toward more selective immune therapies. By targeting axes specific to tumor cells while remaining largely absent from normal tissue, such agents aim to provide a more effective treatment with fewer side effects than broad-spectrum chemotherapy.
HMN-372 is part of a class of small-molecule inhibitors designed to target specific genetic mutations that drive tumor growth. Research suggests it is primarily being evaluated for its efficacy against . HMN-372
: Ongoing trials are investigating how HMN-372 performs when paired with third-generation inhibitors or traditional chemotherapy to improve overall survival and progression-free survival in metastatic cases. Clinical Significance Research suggests it is primarily being evaluated for
: Its primary application has been explored for patients with NSCLC harboring specific mutations, such as EGFR Exon 20 insertion mutations . Though still in the investigational phase